Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Dyadic International received regulatory approval from SAHPRA to initiate a Phase 1 clinical trial for its COVID-19 vaccine candidate, DYAI-100. The company presented significant data at the World Vaccine Congress Europe and announced new collaborations in animal health. As of September 30, 2022, cash and investments totaled $14.2 million. Research and development revenues increased to approximately $880,000 for Q3 2022. Net loss for the quarter was about $1.8 million, consistent with the prior year, but the loss per share improved over nine months.
Dyadic International (NASDAQ: DYAI), a biotechnology firm, has announced participation in key industry events in November 2022, aimed at enhancing its microbial platforms for protein production and biopharmaceutical needs. Key conferences include the RAFT® 14 Conference (Nov 6-9) in Orlando, where CEO Mark Emalfarb will present on Nov 8. Additionally, Dyadic will join the BARDA Industry Day (Nov 15-16) virtually and the Jefferies London Healthcare Conference (Nov 16-19). These events focus on connecting with investors and showcasing advancements in biopharmaceutical products.
Dyadic International, Inc. (NASDAQ: DYAI) will report its third quarter 2022 financial results and conduct a corporate update call on November 10, 2022, at 5:00 PM ET. The company focuses on innovative microbial platforms to enhance global protein production and develop affordable biopharmaceuticals for human and animal health. Its proprietary technologies include the C1-cell protein production platform and Dapibus™ for large-scale manufacturing of proteins. Dyadic aims to expedite the development of biologic products, including its DYAI-100 COVID-19 vaccine candidate.
Dyadic International (NASDAQ: DYAI) has received regulatory approval from the South African Health Products Regulatory Authority for a Phase 1 clinical trial of its DYAI-100 COVID-19 booster vaccine. This randomized, double-blind, placebo-controlled trial will assess the vaccine's safety and preliminary efficacy, with patient enrollment set to begin in South Africa later this year. Dyadic's CEO, Mark Emalfarb, expressed optimism about this milestone, while the partner Rubic Consortium emphasized its significance for improving vaccine access in underserved regions.
Dyadic International (NASDAQ: DYAI) announced that its CEO, Mark Emalfarb, will present at the World Vaccine Congress from October 11-14, 2022 in Barcelona, Spain. The presentation will showcase advancements in expressing Omicron BA.5 and other antigens, aiming to enhance vaccine efficacy against viruses, including COVID-19 variants. Notably, the C1-cell platform allows for efficient antigen production at 10 grams per liter. Collaboration with Dr. Albert Osterhaus will also be highlighted. Interested parties can register for the event or request meetings.
Dyadic International, Inc. (NASDAQ: DYAI) provided updates on its C1 protein production platform, showcasing advancements in protein yield and overall productivity. Key achievements include a nine-fold increase in the expression yield for Nivolumab, and successful expression of several COVID-19 variants, including Omicron. The C1 platform demonstrated significant potential for accelerating vaccine development and lowering production costs. The company anticipates data presentations at upcoming industry conferences and details a planned Phase 1 clinical trial for its COVID-19 recombinant protein booster vaccine.
Dyadic International (NASDAQ: DYAI), a biotechnology firm, has announced its participation in several key industry events in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, followed by a panel at the World Health Organization consultation on September 13-14. Additionally, Dyadic will participate in the Vaccine Technology Summit and BioProcess International. The management will be available for one-on-one meetings during these events to discuss their innovative microbial platforms aimed at enhancing global protein production and biopharmaceutical products.
Dyadic International announced the submission of a Clinical Trial Application (CTA) for its DYAI-100 COVID-19 vaccine to South Africa's SAHPRA, marking a significant milestone for its C1-cell protein production platform. The CTA supports a Phase 1 study focusing on safety and efficacy. The company reported cash and investments of $15.7 million as of June 30, 2022, and noted a decrease in revenue and expenses in the second quarter compared to the previous year. A conference call to discuss financial results is scheduled for August 10, 2022, at 5:00 PM EST.
Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its second-quarter 2022 financial results and host a corporate update call on August 10, 2022, at 5:00 p.m. ET. The company focuses on enhancing its proprietary C1-cell protein production platform for biologic vaccines and drugs, aiming to lower costs and improve performance. Investors can access the live conference via provided dial-in numbers and a webcast link. An archive will be available post-event on Dyadic's website.
Dyadic International (NASDAQ: DYAI), a biotechnology company, announced participation in two key industry events this July 2022.
The Bio-Manufacturing Innovation Summit will be held on July 7-8 at Rutgers University, with a presentation by Mark Emalfarb. The NIIMBL 2022 National Meeting is scheduled for July 26-28 in Washington DC, featuring a poster session by Emalfarb.
Dyadic's management will be available for one-on-one meetings during these events. For more details, visit Dyadic's website.